US 9,808,529 B2
Liquid formulation
Nicholas Bova, Caringbah (AU); Stephen Page, Newtown (AU); and Giuseppe Pippia, Chatswood West (AU)
Assigned to Luoda Pharma Pty Ltd, Caringbah (AU)
Appl. No. 14/401,943
Filed by Luoda Pharma Pty Ltd, Caringbah (AU)
PCT Filed May 17, 2013, PCT No. PCT/AU2013/000522
§ 371(c)(1), (2) Date Nov. 18, 2014,
PCT Pub. No. WO2013/170317, PCT Pub. Date Nov. 21, 2013.
Claims priority of application No. 2012902062 (AU), filed on May 18, 2012.
Prior Publication US 2015/0148335 A1, May 28, 2015
Int. Cl. A61K 47/10 (2017.01); A61K 9/08 (2006.01); A61K 31/401 (2006.01); A61K 45/06 (2006.01); A61K 31/341 (2006.01); A61K 31/497 (2006.01); A61K 31/55 (2006.01); A61K 31/40 (2006.01); A61K 31/501 (2006.01)
CPC A61K 47/10 (2013.01) [A61K 9/08 (2013.01); A61K 31/341 (2013.01); A61K 31/40 (2013.01); A61K 31/401 (2013.01); A61K 31/497 (2013.01); A61K 31/501 (2013.01); A61K 31/55 (2013.01); A61K 45/06 (2013.01)] 7 Claims
 
1. An orally bioavailable liquid formulation comprising 7 wt % to about 65 wt % of the total formulation of propylene glycol and a combination of an inodilator selected from the group consisting of pimobendan, a pharmaceutically acceptable salt thereof, and a veterinary acceptable salt thereof, and an angiotensin converting enzyme inhibitor selected from the group consisting of enalapril, benazepril, a pharmaceutically acceptable salt thereof, and a veterinary acceptable salt thereof; wherein the inodilator and/or the angiotensin converting enzyme inhibitor is present in an amount of about 0.1 wt % to about 50 wt % of the total formulation.